Cargando…
Immune-related adverse events associated with PD-1 and PD-L1 inhibitors for nonsmall cell lung cancer: Protocol for a systematic review and meta-analysis
INTRODUCTION: Nonsmall cell lung cancer accounts for approximately 80% of all lung cancers, and approximately 75% of cases are diagnosed in the middle and late stages of disease. Unfortunately, limited treatment does not improve the prognosis of advanced disease. Monoclonal antibodies targeting prog...
Autores principales: | Sun, Xiaoying, Roudi, Raheleh, Chen, Shangya, Fan, Bin, Li, Hong Jin, Zhou, Min, Li, Xin, Li, Bin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5682790/ https://www.ncbi.nlm.nih.gov/pubmed/29095271 http://dx.doi.org/10.1097/MD.0000000000008407 |
Ejemplares similares
-
Characterization of PD-1/PD-L1 immune checkpoint expression in the pathogenesis of musculoskeletal Langerhans cell histiocytosis: A retrospective study
por: Hashimoto, Kazuhiko, et al.
Publicado: (2021) -
PD-1/PD-L1 pathway activation restores the imbalance of Th1/Th2 and treg/Th17 cells subtypes in immune thrombocytopenic purpura patients
por: Wu, Die, et al.
Publicado: (2019) -
The research status of immune checkpoint blockade by anti-CTLA4 and anti-PD1/PD-l1 antibodies in tumor immunotherapy in China: A bibliometrics study
por: Zhao, Xiaoqin, et al.
Publicado: (2018) -
Expression and clinical significance of PD-L1 and infiltrated immune cells in the gastric adenocarcinoma microenvironment
por: Quan, Qiuying, et al.
Publicado: (2023) -
Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma
por: Li, Zhu, et al.
Publicado: (2016)